Veteran healthcare and life-sciences executive focused on biotech strategy, corporate governance and commercialization planning for specialty pharma and diagnostics. John R. Hanahan served in senior operating and board roles across clinical development and market access, advising capital raises, licensing and M&A for growth-stage companies. Known for bridging R&D and commercial strategy, he is active with private-company boards and strategic investor networks, offering sector-specific operational oversight to institutional and venture investors.
Veteran healthcare and life-sciences executive focused on biotech strategy, corporate governance and commercialization planning for specialty pharma and diagnostics. John R. Hanahan served in senior operating and board roles across clinical development and market access, advising capital raises, licensing and M&A for growth-stage companies. Known for bridging R&D and commercial strategy, he is active with private-company boards and strategic investor networks, offering sector-specific operational oversight to institutional and venture investors.
Brings an operator-to-board investment philosophy emphasizing clinical-stage biotech and specialty pharma where commercial pathways can be accelerated through disciplined development and market-access planning. Prioritizes deals with clear regulatory milestones, differentiated clinical data and definable reimbursement strategies; allocates capital with milestone-weighted tranches and active governance rights. Favors hands-on portfolio involvement—de-risking R&D through strategic licensing, focused C-suite interventions and pragmatic go‑to‑market preparations. Time horizon is patient but outcome-driven, balancing early-stage asymmetric upside against downside protection via validation gates and liquidity-aware exit planning.
Brings an operator-to-board investment philosophy emphasizing clinical-stage biotech and specialty pharma where commercial pathways can be accelerated through disciplined development and market-access planning. Prioritizes deals with clear regulatory milestones, differentiated clinical data and definable reimbursement strategies; allocates capital with milestone-weighted tranches and active governance rights. Favors hands-on portfolio involvement—de-risking R&D through strategic licensing, focused C-suite interventions and pragmatic go‑to‑market preparations. Time horizon is patient but outcome-driven, balancing early-stage asymmetric upside against downside protection via validation gates and liquidity-aware exit planning.
| Trades 468 | Longs Won 321/468 68% | Profit Factor 43.64 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $647,649.22 |
| Average Win $216,961.2 | Best Trade (Dec 31) $9.96M | Sharpe Ratio -10.25 |
| Average Loss -$10,857.02 | Worst Trade (Dec 30) -$223,624.46 | Z-Score 1.92 (94.48%) |
| Commissions $0 | Avg. Trade Length 8m 1w 2d | Expectancy $145,402.91 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 16,949 | 15,254 | 13,559 | 11,864 | 10,169 | 8,475 | 6,780 | 5,085 | 3,390 | 1,695 |